Mirum Pharmaceuticals, Inc. (MIRM)

Mirum Pharmaceuticals' stock has experienced significant activity, with increases of 10.33% in the past month, 13.15% over the past three months, and a year-to-date return of 24.00% as of April 8, 2026. Over the last 12 months, the stock price has increased by 136.19%. Key events include strong financial results and raised guidance, the proposed acquisition of Bluejay Therapeutics, clinical trial progress and milestones, a share offering that caused a stock price decrease, and the achievement of GAAP profitability.

Specific demand seasonality for Mirum Pharmaceuticals' products is not explicitly available. Demand is generally driven by patient diagnosis and the continuous need for therapy rather than seasonal fluctuations. Revenue growth is attributed to broader patient identification, international expansion, and supportive reimbursement environments.

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases, particularly debilitating liver conditions. Its commercial portfolio includes LIVMARLI for cholestatic pruritus in ALGS and PFIC, CHOLBAM for bile-acid synthesis disorders and peroxisomal disorders, and CTEXLI for cerebrotendinous xanthomatosis. The company also has a clinical-stage pipeline with volixibat, brelovitug, and MRM-3379 in development.

Mirum Pharmaceuticals has a global presence with approved products and commercial reach in 33 countries, including major European markets and Japan. The company's corporate office is located in Foster City, California, USA.

Mirum Pharmaceuticals maintains a positive brand reputation due to its focus on rare and orphan diseases. Successful product launches and approvals, strong financial performance, advancements in the clinical pipeline, and global expansion have positively impacted its reputation. There were no significant negative events affecting the company's brand reputation in the past year.

Mirum Pharmaceuticals has a diversified ownership structure with 287 institutional owners and shareholders holding 61,240,809 shares. Major institutional owners include Frazier Life Sciences Management, L.P., Janus Henderson Group Plc, and BlackRock, Inc. Insider ownership stands at 11.62% of outstanding equity, with major individual shareholders including Peter W. Sonsini, Niall O'Donnell, Christopher Peetz, and Michael Grey.